Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection

Simply Wall St.

Mar 28

Qiagen (QGEN) is back in focus after newly published clinical and health economic data supported its QuantiFERON-TB Gold Plus test for tuberculosis detection, together with an upcoming global ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622125389"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622125389\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622125389?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-03-28 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622125389","market":"us","top_or_hot":-1,"title":"Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection","media":"Simply Wall St.","content":"<div>\n<p>Qiagen (QGEN) is back in focus after newly published clinical and health economic data supported its QuantiFERON-TB Gold Plus test for tuberculosis detection, together with an upcoming global ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-qgen/qiagen/news/qiagen-qgen-valuation-check-as-new-quantiferon-tb-data-reinf\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-28 19:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-qgen/qiagen/news/qiagen-qgen-valuation-check-as-new-quantiferon-tb-data-reinf><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Qiagen (QGEN) is back in focus after newly published clinical and health economic data supported its QuantiFERON-TB Gold Plus test for tuberculosis detection, together with an upcoming global ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-qgen/qiagen/news/qiagen-qgen-valuation-check-as-new-quantiferon-tb-data-reinf\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-qgen/qiagen/news/qiagen-qgen-valuation-check-as-new-quantiferon-tb-data-reinf","article_id":"2622125389","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-qgen/qiagen/news/qiagen-qgen-valuation-check-as-new-quantiferon-tb-data-reinf","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622125389","pubTimestamp":1774696024,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Qiagen (QGEN) is back in focus after newly published clinical and health economic data supported its QuantiFERON-TB Gold Plus test for tuberculosis detection, together with an upcoming global QuantiFERON World TB Day online event.\nSee our latest analysis for Qiagen.\nDespite the renewed attention on QuantiFERON, Qiagen’s 30-day share price return of 19.64% and year to date share price return of 17.87% both point to fading near term momentum. The 5 year total shareholder return of 20.51%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","QGEN":"快而精医药","LU1923622614.USD":"Natixis Thematics Meta R/A USD"},"translate_title":"Qiagen(QGEN)评估检查，新的QuantiFERON结核病数据巩固了结核病检测领域的领导地位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":1.5},"content_text":"Qiagen (QGEN) is back in focus after newly published clinical and health economic data supported its QuantiFERON-TB Gold Plus test for tuberculosis detection, together with an upcoming global QuantiFERON World TB Day online event. See our latest analysis for Qiagen. Despite the renewed attention on QuantiFERON, Qiagen’s 30-day share price return of 19.64% and year to date share price return of 17.87% both point to fading near term momentum. The 5 year total shareholder return of 20.51% underlines a weaker longer run outcome. If this TB testing update has you thinking more broadly about diagnostics and health technology, it could be a good moment to scan for other healthcare names involved in AI assisted care using our 34 healthcare AI stocks With Qiagen shares down roughly 18% over 90 days, trading at US$39.07 and sitting close to a 39% intrinsic discount, investors may wonder whether this weakness represents an opportunity or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 29.6% Undervalued Qiagen's most followed valuation narrative points to a fair value of $55.46 compared to the last close at $39.07. This frames the recent pullback in a very different light.  The accelerated adoption of automation and digital workflows in both clinical and research settings, as seen with the development and imminent launch of three new high throughput, digitally connected automated sample prep systems, positions Qiagen to address increasing throughput and efficiency needs, supporting both top line growth and operating margin improvement in coming years.  Read the complete narrative. Want to see what sits behind that fair value gap? The narrative leans heavily on measured revenue growth, firmer margins and a future earnings multiple that has been carefully stress tested. Result: Fair Value of $55.46 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on research budgets and China not weakening further, since softer funding or prolonged regional pressure could quickly challenge the current growth story. Find out about the key risks to this Qiagen narrative. Next Steps With a mix of optimism around potential rewards and concern about the risks that investors have flagged, this is a good time to review the details for yourself and move quickly while sentiment is still forming, then weigh up the 5 key rewards and 1 important warning sign Looking for more investment ideas? If Qiagen has caught your attention, do not stop there. Widen your watchlist now so you are not looking back wishing you had acted sooner.  Spot potential mispricings early and scan a curated set of 61 high quality undervalued stocks that combine quality with appealing entry points. Prioritize strength and resilience by zeroing in on companies filtered through the solid balance sheet and fundamentals stocks screener (39 results). Hunt for fresh opportunities off the beaten path with a screener containing 26 high quality undiscovered gems that many investors may still be overlooking.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Qiagen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}